Latest news
25 items- PRCARsgen Appoints Dr. Raffaele Baffa as Chief Medical OfficerSHANGHAI and BOSTON, April 7, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Raffaele Baffa ("Dr. Baffa") has been appointed as the Chief Medical Officer ("CMO") of the Company, responsible for overseeing the global clinical development strategies and operations for the Company's innovative pipeline product candidates. Dr. Baffa will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited. Dr. Baffa has rich experiences in pharmaceutical industry and research institutes,
- NEWSZiopharm Rebrands As Alaunos TherapeuticsZiopharm Ocology Inc (NASDAQ:ZIOP) has rebranded itself and has changed its name to Alaunos Therapeutics Inc. The Company will trade on NASDAQ under the new ticker symbol "TCRT" to be effective tomorrow. Along with the name change, the Company amended Phase 1/2 IND to add four additional T-cell receptors (TCRs) to its library, increasing the number of eligible patients for the clinical trial. Related: Ziopharm Shares Are Trading Lower After Slashing Workforce By Over 50%. Phase 1/2 TCR-T library trial targeting KRAS, TP53, and EGFR mutations across six solid tumor indications is open for enrollment at Texas' MD Anderson Cancer Center. Dosing is expected to start in 1H of 2022. Additi
- NEWSThe Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 DataHere's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead Hit With FDA Partial Clinical Hold On Multiple Blood Cancer Studies Evaluating Magrolimab-Vidaza Combo Gilead Sciences, Inc. (NASDAQ:GILD) said the U.S. Food and Drug Administration has placed a partial clinical hold on studies evaluating the combination of magrolimab plus Bristol-Myers Squibb Co's (NYSE:BMY) Vidaza due to an apparent imbalance in investigator-reported suspected unexpected serious adverse reactions between study arms. While no clear trend in the adverse reactions or new safety signal has been identified by Gilead at this time, the partial clinical hold is being implem
- SECZIOPHARM Oncology Inc filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Alaunos Therapeutics, Inc. (0001107421) (Filer)
- NEWSZiopharm Oncology Highlights Operational Progress & Rebrands To Alaunos TherapeuticsPhase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications is open for enrollment; continue to expect to dose the first patient in 1H 2022 Phase 1/2 IND amended to include four additional TCRs, bringing the total number of evaluable TCRs to 10, further expanding number of eligible patients In-house cGMP manufacturing facility is operational to support internal clinical development programs Company changes name to Alaunos Therapeutics reflecting renewed focus HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (NASDAQ:ZIOP), a clinical-stage oncology-focused cell therapy comp
- PRZiopharm Oncology Highlights Operational Progress & Rebrands to Alaunos TherapeuticsPhase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications is open for enrollment; continue to expect to dose the first patient in 1H 2022 Phase 1/2 IND amended to include four additional TCRs, bringing the total number of evaluable TCRs to 10, further expanding number of eligible patientsIn-house cGMP manufacturing facility is operational to support internal clinical development programsCompany changes name to Alaunos Therapeutics reflecting renewed focus HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), a clinical-stage oncology-focused cell therapy company, today highlighted rec
- NEWSStocks That Hit 52-Week Lows On FridayDuring Friday's session, 445 companies made new 52-week lows. Noteable 52-Week Lows: Intuitive Surgical (NASDAQ:ISRG) is the largest company in terms of market cap to set a new 52-week low this morning. The company with the smallest market cap to set a new 52-week low was Antelope Enterprise Hldgs (NASDAQ:AEHL). CureVac (NASDAQ:CVAC) was the biggest loser of the morning session, as it dropped 10.02% to reach its new 52-week low. Staar Surgical (NASDAQ:STAA)'s shares had the biggest turnaround, impressively rebounding 0.0% after reaching a new 52-week low. Here is a list of stocks that set new 52-week lows on Friday: Snap (NYSE:SNAP) stock drifted down 1.72% on Friday morning t
- SECZIOPHARM Oncology Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities8-K - ZIOPHARM ONCOLOGY INC (0001107421) (Filer)
- INSIDERSEC Form 4: De Groot Eleanor sold $25,568 worth of shares (20,132 units at $1.27) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 237,106 units (tax withholding)4 - ZIOPHARM ONCOLOGY INC (0001107421) (Issuer)
- NEWS12 Health Care Stocks Moving In Friday's After-Market SessionGainers GBS (NASDAQ:GBS) stock rose 14.28% to $1.44 during Friday's after-market session. At the close, GBS's trading volume reached 299.7K shares. This is 34.56% of its average volume over the last 100 days. The market value of their outstanding shares is at $21.4 million. Brickell Biotech (NASDAQ:BBI) shares moved upwards by 11.11% to $0.26. Trading volume for this security closed at 527.2K, accounting for 20.85% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $29.6 million. Zosano Pharma (NASDAQ:ZSAN) stock rose 6.66% to $0.54. Zosano Pharma's trading volume hit 130.4K shares by close, accounting for 5.99% of its average vo
- INSIDERSEC Form 4 filed by Lackey Melinda4 - ZIOPHARM ONCOLOGY INC (0001107421) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lackey Melinda3 - ZIOPHARM ONCOLOGY INC (0001107421) (Issuer)
- NEWS12 Health Care Stocks Moving In Monday's After-Market SessionGainers ACADIA Pharmaceuticals (NASDAQ:ACAD) stock rose 24.26% to $24.11 during Monday's after-market session. Today's trading volume for this security ended up closing at 1.3 million shares, which is 106.1 percent of its average volume over the last 100 days. The company's market cap stands at $3.8 billion. Cumberland (NASDAQ:CPIX) stock increased by 8.64% to $7.54. At the close, Cumberland's trading volume reached 638.8K shares. This is 16.19% of its average volume over the last 100 days. The company's market cap stands at $111.6 million. Aptinyx (NASDAQ:APTX) stock moved upwards by 8.29% to $2.35. The market value of their outstanding shares is at $159.1 million. TherapeuticsMD (NASDA
- INSIDERSEC Form 3 filed by new insider Wong Michael3 - ZIOPHARM ONCOLOGY INC (0001107421) (Issuer)
- INSIDERSEC Form 4: Boyle Kevin S. Sr. bought $14,000 worth of shares (10,000 units at $1.40), increasing direct ownership by 1% to 885,000 units4 - ZIOPHARM ONCOLOGY INC (0001107421) (Issuer)
- PRZiopharm Oncology Presents Preclinical Data Supporting TCR-T Library Approach at the Society for Immunotherapy of Cancer 2021 Annual MeetingHOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced the presentation of preclinical data highlighting the potential of neoantigen-specific TCR-T cells for the treatment of solid tumors at the Society for Immunotherapy of Cancer 2021 Annual Meeting. "We are pleased to share preclinical data demonstrating the versatility of our Sleeping Beauty technology to develop neoantigen-specific TCR-T cells with the potential to address a wide range of solid tumor indications," commented Raffaele Baffa, M.D., Ph.D., Chief Medical Officer & EVP, Research & Development. "Our TCR-T library approach allows us to develop safe, effe
- ANALYSTRaymond James reiterated coverage on ZIOPHARM Oncology with a new price targetRaymond James reiterated coverage of ZIOPHARM Oncology with a rating of Market Perform and set a new price target of $2.00 from $3.00 previously
- SECSEC Form 10-Q filed by ZIOPHARM Oncology Inc10-Q - ZIOPHARM ONCOLOGY INC (0001107421) (Filer)
- PRZiopharm Oncology Reports Third Quarter 2021 Financial Results and Provides Business UpdateHOUSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced financial results for the third quarter ended September 30, 2021 and provided a business update. "I am impressed by the quality and dedication of our team at Ziopharm who all are diligently working to transform our cutting-edge scientific research into meaningful clinical progress. Last quarter we made the decision to restructure the organization and focus our efforts on advancing our differentiated TCR-T library towards the clinic," said Kevin S. Boyle, Sr., Chief Executive Officer at Ziopharm Oncology. "We are making excellent progress to operationa
- SECZIOPHARM Oncology Inc filed SEC Form 8-K: Leadership Update8-K - ZIOPHARM ONCOLOGY INC (0001107421) (Filer)
- PRZiopharm Oncology to Report Third Quarter Financial Results on November 8, 2021HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced that it will report financial results for the third quarter ended September 30, 2021 on Monday, November 8, 2021, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 4:30 p.m. ET to provide a corporate update and review the financial results. The conference call can be accessed by dialing 877-451-6152 (United States) or 201-389-0879 (International) with the conference code 13724384. A live webcast may be accessed using the link here, or by visiting the "Investors" section of the Ziopharm website at w
- 13D/GSEC Form SC 13G/A filed by ZIOPHARM Oncology Inc (Amendment)SC 13G/A - ZIOPHARM ONCOLOGY INC (0001107421) (Subject)
- INSIDERSEC Form 4: Vieser Jaime bought $191,000 worth of shares (100,000 units at $1.91), increasing direct ownership by 17% to 705,321 units4 - ZIOPHARM ONCOLOGY INC (0001107421) (Issuer)
- SECZIOPHARM Oncology Inc filed SEC Form 8-K: Leadership Update8-K - ZIOPHARM ONCOLOGY INC (0001107421) (Filer)
- SECZIOPHARM Oncology Inc filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ZIOPHARM ONCOLOGY INC (0001107421) (Filer)
ZIOP FAQ
6 questionsWhat does ZIOPHARM Oncology Inc do?
ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack...Where does ZIOP stock trade?
ZIOPHARM Oncology Inc (ZIOP) is listed on NASDAQ.What sector and industry is ZIOP in?
ZIOPHARM Oncology Inc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ZIOP?
ZIOPHARM Oncology Inc has had 3 recent analyst actions on file. The most recent action was from Raymond James: Market Perform with a $200.00 price target on 2021-11-09. Recent price targets range from $200.00 to $300.00.What companies are similar to ZIOP?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ZIOP side-by-side with any of them on Quantisnow.How can I track ZIOP on Quantisnow?
Quantisnow aggregates ZIOPHARM Oncology Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ZIOP to receive live email and push alerts on every new disclosure.